PCOS表型对未成熟卵母细胞体外成熟结局的影响
本研究为单中心回顾性队列研究,纳入320例首次接受IVM的PCOS患者,比较不同表型间的累积活产率。多因素回归显示A/HOP表型CLBR最高,C/HP和D/OP表型CLBR较低(OR分别为0.26和0.47,P=0.03)。
要点
- PCOS表型A/HOP患者IVM后累积活产率最高。
- C/HP和D/OP表型CLBR显著低于A/HOP(P=0.03)。
- 不同表型间早期流产率存在显著差异(P=0.04)。
核心结论
- PCOS表型与IVM后累积活产率显著相关,A/HOP表型CLBR最高,C/HP和D/OP表型较低(P=0.03)。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年4月至2018年1月期间320例首次IVM周期的PCOS患者。
主要发现
- A/HOP组CLBR为40.0%(56/140),C/HP组为15%(3/20),D/OP组为33.1%(53/160),单因素分析P=0.07。
- 多因素回归中,以A/HOP为参照,C/HP的OR为0.26(CI 0.06-1.05),D/OP的OR为0.47(CI 0.25-0.88),P=0.03。
- 早期流产率A/HOP为19.5%(24/123),C/HP为26.7%(4/15),D/OP为10.2%(13/128),P=0.04。
- 获卵数(COC)A/HOP为25.9±19.1,C/HP为18.3±9.0,D/OP为19.8±13.5(P=0.004);成熟卵母数分别为12.4±9.3、6.5±4.2、9.1±6.9(P<0.001)。
- 首次胚胎移植后阳性hCG率A/HOP为44.7%(55/123),C/HP为40.0%(6/15),D/OP为36.7%(47/128),P=0.56。
临床怎么用
- IVM可作为PCOS患者ART的可选方案,尤其对A/HOP表型者可能获益更明显。
- IVM项目中应重视PCOS表型的筛选,以优化患者选择。
局限性
- 回顾性研究可能存在未测量混杂因素和PCOS表型错分。
- C/HP表型样本量过小(n=20),无法得出该亚组的可靠结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the phenotype of patients with polycystic ovary syndrome (PCOS) affect clinical outcomes of ART following in-vitro oocyte maturation? SUMMARY ANSWER: Cumulative live birth rates (CLBRs) after IVM were significantly different between distinct PCOS phenotypes, with the highest CLBR observed in patients with phenotype A/HOP (= hyperandrogenism + ovulatory disorder + polycystic ovaries), while IVM in patients with phenotype C/HP (hyperandrogenism + polycystic ovaries) or D/OP (ovulatory disorder + polycystic ovaries) resulted in lower CLBRs (OR 0.26 (CI 0.06-1.05) and OR 0.47 (CI 0.25-0.88), respectively, P = 0.03). WHAT IS KNOWN ALREADY: CLBRs in women with hyperandrogenic PCOS phenotypes (A/HOP and C/HP) have been reported to be lower after ovarian stimulation (OS) and ART when compared to CLBR in women with a normo-androgenic PCOS phenotype (D/OP) and non-PCOS patients with a PCO-like ovarian morphology (PCOM). Whether there is an influence of the different PCOS phenotypes on success rates of IVM has been unknown. STUDY DESIGN, SIZE, DURATION: This was a single-centre, retrospective cohort study including 320 unique PCOS patients performing their first IVM cycle between April 2014 and January 2018 in a tertiary referral hospital. PARTICIPANTS/MATERIALS, SETTING, METHODS: Baseline patient characteristics and IVM treatment cycle data were collected. The clinical outcomes following the first IVM embryo transfer were retrieved, including the CLBR defined as the number of deliveries with at least one live birth resulting from one IVM cycle and all appended cycles in which fresh or frozen embryos were transferred until a live birth occurred or until all embryos were used. The latter was considered as the primary outcome. A multivariate regression model was developed to identify prognostic factors for CLBR and test the impact of the patient's PCOS phenotype. MAIN RESULTS AND THE ROLE OF CHANCE: Half of the patients presented with a hyperandrogenic PCOS phenotype (n = 140 A/HOP and n = 20 C/HP vs. n = 160 D/OP). BMI was significantly different between phenotype groups (27.4 ± 5.4 kg/m2 for A/HOP, 27.1 ± 5.4 kg/m2 for C/HP and 23.3 ± 4.4 kg/m2 for D/OP, P < 0.001). Metformin was used in 33.6% of patients with PCOS phenotype A/HOP, in 15.0% of C/HP patients and in 11.2% of D/OP patients (P < 0.001). Anti-müllerian hormone levels differed significantly between groups: 12.4 ± 8.3 µg/l in A/HOP, 7.7 ± 3.1 µg/l in C/HP and 10.4 ± 5.9 µg/l in D/OP patients (P = 0.01). The number of cumulus-oocyte complexes (COC) was significantly different between phenotype groups: 25.9 ± 19.1 COC in patients with phenotype A/HOP, 18.3 ± 9.0 COC in C/HP and 19.8 ± 13.5 COC in D/OP (P = 0.004). After IVM, patients with different phenotypes also had a significantly different number of mature oocytes (12.4 ± 9.3 for A/HOP vs. 6.5 ± 4.2 for C/HP vs. 9.1 ± 6.9 for D/OP, P < 0.001). The fertilisation rate, the number of usable embryos and the number of cycles with no embryo available for transfer were comparable between the three groups. Following the first embryo transfer, the positive hCG rate and LBR were comparable between the patient groups (44.7% (55/123) for A/HOP, 40.0% (6/15) for C/HP, 36.7% (47/128) for D/OP, P = 0.56 and 25.2% (31/123) for A/HOP, 6.2% (1/15) for C/HP, 26.6% (34/128) for D/OP, respectively, P = 0.22). However, the incidence of early pregnancy loss was significantly different across phenotype groups (19.5% (24/123) for A/HOP, 26.7% (4/15) for C/HP and 10.2% (13/128) for D/OP, P = 0.04). The CLBR was not significantly different following univariate analysis (40.0% (56/140) for A/HOP, 15% (3/20) for C/HP and 33.1% (53/160) for D/OP (P = 0.07)). When a multivariable logistic regression model was developed to account for confounding factors, the PCOS phenotype appeared to be significantly correlated with CLBR, with a more favourable CLBR in the A/HOP subgroup (OR 0.26 for phenotype C/HP (CI 0.06-1.05) and OR 0.47 for phenotype D/OP (CI 0.25-0.88), P = 0.03)). LIMITATIONS, REASONS FOR CAUTION: These data should be interpreted with caution as the retrospective nature of the study holds the possibility of unmeasured confounding factors and misassignment of the PCOS phenotype. Moreover, the sample size for phenotype C/HP was too small to draw conclusions for this subgroup of patients. WIDER IMPLICATIONS OF THE FINDINGS: Caucasian infertile patients with a PCOS phenotype A/HOP who undergo IVM achieved a higher CLBR than their counterparts with C/HP and D/OP. This is in strong contrast with previously reported outcomes following OS where women with PCOS and hyperandrogenism (A/HOP and C/HP) performed significantly worse. For PCOS patients who require ART, the strategy of OS followed by an elective freeze-all strategy remains to be compared with IVM in a prospective fashion; however, the current data provide support for IVM as a valid treatment option, especially in the most severe PCOS phenotypes (A/HOP). Our data suggest that proper patient selection is of utmost importance in an IVM programme. STUDY FUNDING/COMPETING INTEREST(S): The clinical IVM research has been supported by research grants from Cook Medical and Besins Healthcare. All authors declared no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Mackens S, Pareyn S, Drakopoulos P, et al. Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact? Hum Reprod. 2020. PMID: 32951028. doi:10.1093/humrep/deaa190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。